Int Urol Nephrol. 2025 Dec 17. doi: 10.1007/s11255-025-04965-6. Online ahead of print.
ABSTRACT
AIMS: This study aims to evaluate differences in adiposopathy and specific inflammatory biomarkers between type 2 diabetes mellitus (T2DM) and non-T2DM patients across various stages of chronic kidney disease (CKD). In addition, it explores potential pathways through which sodium-glucose cotransporter 2 inhibitors (SGLT2i) impact renal outcomes via adipose tissue.
MATERIALS AND METHODS: An observational prospective study was conducted on 143 CKD patients divided into 2 groups: SGLT2i cohort (n = 31) and standard-of-care (SoC) cohort (n = 112). Clinical and analytical data were collected upon recruitment (T0) as well as after 8 months of follow-up (T8).
RESULTS: At T0, patients under the SGLT2i group showed higher significance for cardiovascular upload versus those in SoC treatment, as well as higher values across several inflammation parameters (IL-6, TNF-α, ferritin). At T8, renal function improved in the SGLT2i group in relation to the SoC, accompanied by a decrease in most inflammatory and adiposopathy biomarkers, mainly leptin. Notably, dapagliflozin use (n = 20) was associated with significantly reduced leptin levels and stabilization of TNF-α concentrations vs. SoC at T8.
CONCLUSION: SGLT2i treatment, and particularly dapagliflozin, modulates both adiposopathy and systemic inflammation while slowing down renal function loss, demonstrating benefits for CKD patients regardless of diabetes status.
PMID:41405774 | DOI:10.1007/s11255-025-04965-6